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ABSTRACT – Purpose. We have previously shown favorable in vitro gut permeability for three novel dipeptide esters of glucosamine (GlcN) likely facilitated by the peptide transporter 1 (PepT1). Herein, we report
the development of a novel assay for the determination of bioavailability of the peptide ester of interest, the
anti-inflammatory properties of a glycine-valine ester derivative of GlcN (GVG) as well as its pharmacokinetics
under healthy and inflammatory conditions. Methods. A pre-column derivatization (with 9fluorenylmethoxycarbonyl) HPLC assay was developed to study bioavailability of GVG, GlcN or cleaved GlcN
in the rats that were cannulated in their right jugular vein for blood collection. The compounds of interest were
orally administered to both healthy and arthritic rats. Serial blood samples and urine were collected and assayed
for the compounds. The stability of the GVG was also tested after incubation with the rat feces. Efficacy of
GVG was tested in inflamed rats (injection of 0.2 mL of Mycobacterium butyricum in squalene) following GVG
(20 and 30 mg/kg/day GlcN equivalent) or GlcN (20 and 90 mg/kg/day) administration. Arthritis index was
calculated at the end of the experiment. Results. The assay was linear (ranged between 0.05-20 μg/mL) and
reproducible (intra- and inter-day<10%). Among the tested compounds, only GVG showed a significantly
higher plasma concentrations and urinary excretion than GlcN (≈3-fold increase). GVG showed a favorable
stability in the rat feces. Adjuvant arthritis was completely prevented with doses greater than 20 mg/kg/day with
GVG being 3-fold more potent than GlcN. Conclusion. The examined glycine-valine-GlcN di-peptide
aminosugar is a potent anti-inflammatory compound due to its favorable properties to deliver GlcN into the
systemic circulation.
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
___________________________________________________________________________________
and di-peptide GlcN ester and amide derivatives
(6). Among the tested prodrugs, an ester derivative,
Gly-Val-COO-GlcN (GVG) showed increased in
vitro permeability through everted rat gut, which
was, at least in part, efficiently mediated by PepT1.
GVG was relatively stable in the gut, readily
crossed the gut wall in vitro and was rapidly
hydrolyzed to yield the parent drug (GlcN) after
incubation with liver homogenates; therefore, it
appeared to be a promising candidate for further
investigation.
The first aim of this study was to investigate
the in vivo bioavailability of three di-peptide esters
of GlcN, GVG, phenylalanine-phenylalanine-COOGlcN (FFG), and valine-glycine-COO-GlcN
_________________________________________

INTRODUCTION
Glucosamine (GlcN) is a naturally occurring
amino-sugar with anti-inflammatory properties (13). However, the oral bioavailability of GlcN is
limited and, since, at least outside Europe, it is not a
regulated compound, the quality of the marketed
products and also those used in clinical trials are
questionable (4). The latter issues have been
suggested to be, at least in part, behind the
controversy in the effectiveness of GlcN.
Nevertheless, GlcN is vastly used in the treatment
of osteoarthritis (OA) (5).
One approach for improving the oral bioavailability
of poorly absorbed polar drug such as GlcN is to
synthesize
prodrugs
that
facilitate
their
translocation across the intestinal wall by the di/tripeptide oligopeptide transporter (PepT1). Recently,
we have designed and synthesized several mono-
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acid, naphthalene ethylene diamine, and
sulphanilamide were purchased from SigmaAldrich (St. Louis, MO, USA). Mycobacterium
butyricum was purchased from Difco (Detroit, MI,
USA). Squalene was purchased from Kodak
(Rochester, NY, USA). HPLC grade acetonitrile
and water were purchased from Caledon
Laboratories Ltd, (ON, Canada). All other
chemicals and solvents were commercial products
of analytical or HPLC grades.

(VGG), relative to GlcN. For this purpose, we
developed a sensitive HPLC assay for simultaneous
measurement of GlcN and its ester derivative,
GVG, based on fluorescence detection. Both GlcN
and GVG lack chromophores; hence, they were
derivatized
with
9-fluorenylmethoxycarbonyl
(Fmoc), a highly fluorescent compound (7,8).
The second aim of this study was to assess
GVG stability in the rat feces. It has been
previously shown that GlcN can be degraded by
feces, which in turn, causes reduced bioavailability
(9).
The third aim of this study was to explore the
efficacy of GVG in prevention of experimental
inflammation in a rat model of adjuvant arthritis
(AA), which has been used for decades to test
antirhematoid drugs (10). There are several studies
indicating that GlcN at high doses, which is
associated with high plasma concentrations, is
effective
in
prevention
and
controlling
inflammatory conditions including AA (1,2). We,
hence, hypothesized that a GlcN prodrug (e.g.
GVG) with a relatively high bioavailability is a
novel drug suitable for the treatment of
inflammatory conditions such as AA. The new
GlcN derivative can produce therapeutic GlcN
levels with smaller daily doses compared to GlcN.
This is expected to improve patient’s compliance as
the available product are excessively large; a
typical 500 mg tablet of GlcN weighs 1.4 g.
Finally, we investigate the possible effect of
inflammation on the pharmacokinetic of GVG.
Inflammation is known to cause alteration on the
expression of several transporters (11). It has been
reported that Dextran sulfate sodium-induced rat
colitis does not alter PepT1 substrate bioavailability
despite certain modifications in the mRNA
expression (12).

Animals
The experimental protocol was approved by the
University of Alberta Animal Care Committee.
Male Sprague–Dawley rats (250–280 g) were
acclimatized in a temperature-controlled room with
a 12:12 h dark/light cycle and fed with standard
rodent chow food containing crude protein 23%,
crude fat 4.5%, crude fiber 6%, ash 8%, and
mineral 2.5%.
Simultaneous HPLC assay for GlcN and GVG
Plasma concentration and/or urinary excretion of
GlcN was determined and used as a measure of
bioavailability for all tested compounds. In
addition, for GVG only, the intact pro-drug was
measured to test its presence in various biological
samples. The HPLC system consisted of a
Shimadzu Prominence HPLC system (Mandel
Scientific, Guelph, ON Canada) equipped with a
RF-10AxL fluorescence detector, a LC-20AT
pump, a DGU-20A5 degasser, a SIL-20A autosampler, a CTO-20AC column oven, a CBM-20A
communication bus module and a Phenomenex C18
(100 mm x 4.6 mm, id 3 µm) reversed phase
column guarded with a security guard cartridge C18
(4 mm x3 mm) column. The gradient mobile phase
consisted of 0.1% acetic acid in HPLC-grade water
(A) and acetonitrile (B) which was run at 1
mL/min; the gradient system commenced and
continued for 17 min with 24% B followed by an
increase of B to 90% in 1 min. The composition
was maintained for 10 min and decreased back to
24% B in 1 min. Column oven temperature was set
at 37º C. The detection was carried out at excitation
and emission wavelength of 256 nm and 315 nm,
respectively. The sample run time was 38 min. The
peak height was used for all calculations.
Adequate amount of GlcN.HCl or GVG.HCl
was dissolved in 10 mL water to yield a 1 mg/mL
(based on free base) stock solution of each

MATERIALS AND METHODS
Chemicals
The examined dipeptides (GVG, FFG and VGG)
were synthesized in our lab based on a previously
described
method
(6).
D-(+)-GlcN,
9fluorenylmethoxycarbonyl chloride (Fmoc-Cl),
mannosamine HCl, 1-aminoadmantane HCl
(amantadine), boric acid, sodium hydroxide, lactic
dehydrogenase, aspergillus nitrate reductase , FAD,
NADPH, tris base, tris hydrochloride, sodium
nitrite, sodium nitrate, pyruvic acid, phosphoric
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another 24 h. Aliquots of the samples were
derivatized and analyzed after each freeze-thaw
cycle. At the end of the stability experiments, the %
accuracy and CV% were calculated.

compound. The stock solutions were further diluted
with water to give standard solutions containing
0.1, 1, 10, 20 and 40 μg/mL. Aliquots of 0.1 mL
plasma were spiked with the standard solutions to
yield the calibration solutions containing 0.05, 0.5,
5, 10 and 20 μg/mL of each compound. The
standard curves were constructed by plotting
GlcN:IS or GVG:IS peak height ratio versus the
added concentration of GlcN or GVG. A 30 μg/mL
mannosamine HCl (IS) solution was used as the
internal standard (IS). Fmoc-chloride was used as
the derivatizing reagent at a concentration of 8 mM
in acetonitrile. Borate buffer (0.2 M) was prepared
by dissolving 6.18 g boric acid in 425 mL water
followed by pH adjustment to 8.5 using NaOH (10
M). A 300 mM solution of amantadine was
prepared in acetonitrile/water (1:1, v/v) and was
used as a scavenger for the unreacted Fmocchloride.
To 0.1 mL of rat plasma was added 50 μL of IS
and proteins precipitated with 200 μL of cold
acetonitrile followed by 1 min vortex-mixing and
centrifugation for 3 min at 10,000 g. 100 μL of the
supernatants were transferred into clean test tubes
and 50 μL of each borate buffer and a freshly
prepared Fmoc-chloride solution were added. After
1 min vortex-mixing the samples were incubated in
a water bath at 30º C for 30 min. Subsequently, 50
μL of amantadine was added and samples were
diluted with 1 mL acetonitrile/water (1:1) followed
by injection of aliquots (5 μL) into HPLC.
Three calibration curves were prepared on the
same day to determine intra-day variability. The
experiment was repeated on three different days to
determine the inter-day variability. The accuracy
was determined from % error = (mean observed
concentration – added concentration) x100/ added
concentration. The coefficient of variation (CV%)
was used to estimate the assay precision.
The percent recovery of GlcN, GVG, and IS
from plasma was estimated from % recovery =
(compound peak height in plasma sample /
compound peak height in water sample) x 100.
In order to determine the short term stability,
samples (0.05, 0.5, 5 and 20 μg/mL) were
derivatized and analyzed at 0, 4, 8 and 24 h postderivatization. In order to measure the freeze and
thaw stability, samples were prepared and kept in
the freezer at -20º C for 24 h. The samples were
removed from the freezer and allowed to thaw at
room temperature followed by refreezing for

Bioavailability of ester derivatives
Under oxygen/methoxyflurane anaesthesia, animals
were cannulated in their right jugular vein as
previously described (1). Briefly, a polyethylene
cannula (Dow Corning Corp., Midland, MI, USA)
tipped with 2 cm of silastic tubing (Becton
Dickinson, Sparks, MD, USA) was inserted into
their right jugular vein. Rats were allowed to
recover overnight. Food was withdrawn from the
animals 12 h before dosing. They were randomly
assigned into four different groups (n=8-11/group)
and received either GlcN, or one of its ester
prodrugs (GVG, FFG, or VGG) at the equivalent to
100 mg/kg of GlcN and serial blood samples were
collected just before administration and at 0.25, 0.5,
0.75, 1, 1.5, 2, 3, and 4 h post-dose. Samples were
collected into heparinized tubes and plasma
separated immediately by centrifugation. Total
urine output was also collected over a period of 24
h. All samples were stored at -20º C until analyzed.
Fecal stability of GVG
Fecal pellets were collected from healthy rats (one
pellet from each rat; n = 6) and placed in 50 mL
centrifuge tube, soften by addition of 25 mL
deionised water, vortex-mixed for 10 min and
centrifuged at 2500 rpm for 8 min. The fecal
suspension (1 mL) was transferred into a 1.5 mL
microcentrifuge tube and centrifuged at 8,300 g for
5 min. The supernatant was immediately spiked
with GVG (1.25 mg per each sample). The first set
of samples was incubated at 37º C for 2 h to assess
the effect of aerobic intestinal micro-flora. Air was
removed from the tubes of the second set of
samples (n=6) by blowing nitrogen (N2) into the
test tubes. Thereafter, samples were incubated at
37º C for 2 h to assess the effect of anaerobic
intestinal micro-flora. The third set of samples was
placed in a 4º C refrigerator for 2 h in order to study
the effect of the feces compositions on GVG
stability. A GVG solution (1.25 mg) with addition
of no feces was set separately as a negative control.
Control sample was incubated for 2 h at 37º C. At
the end of the experiment the amount of GVG was
determined using HPLC.
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moderate swelling, and four was involvement of
several joints and ankle with severe swelling. Each
forepaw was scored on a 0–3 basis scoring system
where 0 was involvement of none of the joints, one
was involvement of single joint, two was
involvement of more than one joint and/or wrist,
and three was involvement of wrist and joints with
moderate-to-severe swelling.

Effect of inflammation on GVG bioavailability
Animals were randomly divided into two groups:
Inflamed or healthy control (n = 6). Adjuvant
arthritis was induced in the inflamed animals by
injecting 0.2 mL of Mycobacterium butyricum in
squalene (50 mg/mL) in the tail base. Healthy rats
were injected 0.2 mL of saline. On day 14, when
the sign and symptoms of arthritis appear in the
inflamed group (1), all animals were cannulated in
their right jugular vein. After an overnight recovery
period, a dose of GVG (equivalent to 100 mg/kg of
GlcN base) was administered and serial blood
samples were collected before dosing and at 0.25,
0.5, 0.75, 1, 1.5, 2, 3, and 4 h post dosing. The total
0-24 h urine output was also collected for the
determination of GVG and GlcN.

Data treatment and statistical analysis
The non-compartmental approach was used to
calculate pharmacokinetic parameters. The area
under the plasma concentration-time curve (AUC)
0-4 h post-dose was calculated using the trapezoidal
method. The peak concentration (Cmax) and the time
of its attainment (tmax) were the experimentally
observed values. The percent urinary excretion was
estimated from (total excreted in urine in 24 h/dose)
X 100.
Data are presented as mean ± SD. Differences
between two means were assessed using the
Student’s t-test (Table 2). For more than two
means, we used the one-way ANOVA followed by
Bonferroni post-test. All statistical analyses were
carried out using Prism software (GraphPad
Software Inc., San Diego, CA, USA) at p < 0.05.

GVG efficacy in prevention of adjuvant arthritis
Rats were randomly assigned into 6 groups (n=6
/group): Control-Healthy, Control-Inflamed, GlcN20, GVG-20, GVG-30, and GlcN-90. On day one,
all inflamed rats were injected 0.2 mL of
Mycobacterium butyricum in squalene (50 mg/mL).
Control-Healthy animals were injected 0.2 mL of
normal saline. GlcN or GVG administration was
commenced on the first day of experiment as a
preventive measure. In this study we chose 2 daily
GlcN equivalent dosage regimens: First, 30 mg/kg
GVG vs 90 mg/kg GlcN to confirm efficacy at
doses higher the minimum effective GlcN dose (40
mg/kg, (13)), and second, 20 mg/kg GVG versus 20
mg GlcN, a regimen below the minimum effective
GlcN dose.
During the experiment, body weight gain and
paw thickness (using a caliper with a sensitivity of
25 µm, Mitutoyo Canada Inc., Toronto, ON) were
measured daily. On the last day of experiment,
serum nitrite was measured using a previously
described method (14). Nitrite standard curves were
linear over the concentration range of 3 - 200 µM
(r2 ≥ 0.99, coefficient of variation ≤10%).
On day 18 after injection of the adjuvant,
arthritis index was calculated according to a
previously described method (15). A maximum
score of 14 could be assigned to each animal as
followed: On a 0–4 basis hind paws were scored
where zero was no virtual sign of arthritis, one was
involvement of a single joint, two was involvement
of more than one joint and/or ankle, three was
involvement of several joints and ankle with

RESULTS
Simultaneous HPLC assay for GlcN and GVG
The HPLC peaks for Fmoc derivatized GlcN and
mannosamine (IS) appeared as pairs of anomers as
has been previously reported (8). The anomers
resolved at 11.6 and 14.1 min for the IS and 12.7
and 15.5 min for GlcN (Figure 1). The second peak
of each compound was used in order to quantify the
samples. GVG resolved as a single peak at a
retention time of 17.7 min. No interfering peak was
observed in the blank rat plasma or urine samples.
The assay was linear over the range of 0.05-20
μg/mL for both GVG and GlcN in rat plasma
(r2≥0.99). The lowest limit of quantification was set
at 50 ng/mL for both compounds. The peak height
measurement approach provided lower variability
in response than that of the peak area, hence, the
former was used throughout. The inter- and intraday variations were less than 10% for all
concentrations and the accuracy ranged from -1.4 to
2.4% for GlcN and -6 to 8% for GVG.
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Figure 1. HPLC chromatograms of (a) blank rat plasma, (b) rat plasma at t=4 h post-dosing (GVG 100 mg/kg); only GlcN
peaks appears in plasma after GVG administration, and (c) blank rat plasma spiked with 1 µg/mL GlcN and GVG. Keys:
M, mannosamine (IS); G, GlcN; GVG, Gly-Val-COO-GlcN

The percent recovery of the IS from rat plasma was
96.1±3. The % recovery of GVG was 99±5.3,
98.2±5.1, 97±3.7, 95.9±9.2, and 94.2±7.3 for the
0.05, 0.5, 5, 10, and 20 μg/mL samples in rat
plasma, respectively. Percent recovery of GlcN
from rat plasma appeared to be 105±6.1, 97.8±7,
103.2± 4.3, 103.3±2.2, and 99.8±6.2% from the
0.05, 0.5, 5, 10, and 20 μg/mL samples,
respectively.
Derivatized GVG and GlcN were stable in all
plasma samples during the analysis process and 24
h after derivatization; stability was > 91 % for all
samples. GVG and GlcN were also appeared to be
stable in rat plasma after three freeze and thaw
cycles.

(Table 1). FFG and VGG only showed an
insignificant trend toward increased bioavailability
as compared to GlcN. GVG also exhibited a
significant increase in percent of dose excreted in
the urine as compared to the other tested
compounds. No significant differences were

Bioavailability of GlcN versus its ester
derivatives
Figure 2 depicts the mean plasma concentration of
GlcN after administration of equivalent doses (100
mg/kg of GlcN base) of GlcN or its ester
derivatives. All compounds were rapidly absorbed
(tmax ≤ 0.5 h). However, among all tested
compounds, only GVG showed a significantly
higher oral bioavailability as compared to GlcN

Figure 2. Mean GlcN plasma concentration (±SD)
versus time profile following oral administration of
GlcN or the ester derivatives of GlcN to rats (n=811/group). All doses were equivalent to100 mg/kg of
GlcN base.
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Table 1. Bioavailability parameters of GlcN and its ester derivatives
Compound
GlcN
VGG
Cmax (µg/mL)
3.7±0.6a
4.4 ± 1.4a
AUC0-4 (µg.h/mL)

6.6±1.2c

7.8 ± 1.6c

FFG
4.7 ± 1.6a

GVG
14.6 ± 4.9b

8.1 ± 1.5c

19.2 ± 3.7d

% of dose excreted in 2.2±0.3e
2.6 ± 0.5e
2.8 ± 0.7e
6.8 ± 0.6f
the urine0-24
For all compounds, a single oral dose equivalent to 100 mg/kg of GlcN base was orally administered to the animals (n=810/group). Data are shown as mean± SD. Different superscript characters indicate significant differences between means in
a row (p < 0.05).

noticed among GlcN, FFG, and VGG in any of the
calculated pharmacokinetic parameters.
No intact GVG was detected in plasma or urine
after its oral administration.

and the percent of dose excreted in the urine in 24 h
(Figure 4 and Table 2).

Fecal stability of GVG
Figure 3 depicts the percent remaining of GVG
after 2 h incubation under control (no feces),
aerobic, and anaerobic conditions at 37 and 4º C.
Incubation of GVG with rat faces resulted in almost
33% loss in all samples. There were no significant
differences between the amounts of GVG that
remained at the end of the experiment under
aerobic, anaerobic, or 4º C conditions. At the end
of the experiment, approximately 97% of GVG
remained intact in the control samples.
Figure 4. Mean (n=6/group) plasma concentration
(±SD) versus time profiles of glucosamine in control and
inflamed rats following oral administration of a single
dose equivalent to 100 mg/kg GlcN base.

GVG efficacy in prevention of adjuvant arthritis
Adjuvant arthritis emerged in the rats (ControlInflamed) that received Mycobacterium butyricum
but were not treated with either GlcN or GVG.
They exhibited significant increase in paw
thickness (Figure 5) as compared to the ControlHealthy animals and, at the end of the experiment
(day 18) had arthritis index of 9.1 ± 0.8. No sign of
arthritis was observed in Control-Healthy group as
well as in the rats that were treated with 90
mg/kg/day GlcN (GlcN-90) or 20 and 30
mg/kg/day GVG. Administration of 20 mg/kg/day
GlcN (GlcN-20) did not prevent adjuvant arthritis
but the severity of the disease was significantly less
than those observed for Control-Inflamed (arthritis
index, 4.1 ± 1.1).

Figure 3. The average percent GVG remaining after 2 h
incubation at 37º C (control, aerobic and anaerobic) or at
4º C. Error bars represent standard deviation. The same
character indicates no significant difference between
means at p < 0.05; n=6/group.

Effect of inflammation on GVG bioavailability
Inflammation did not significantly alter the oral
bioavailability of a single oral dose of GVG (100
mg/kg of GlcN base) as no significant differences
were noticed between the groups in Cmax, AUC0–4
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Table 2. Bioavailability parameters of GVG in control and inflamed rats (n=6/group)
Group
Inflamed
Cmax (µg/mL)
14.01 ± 1.7

Control
14.25 ± 0.6

AUC0-4 (µg.h/mL)

19.1 ± 1.1

18.97 ± 0.5

% of dose excreted in the urine0-24

7.1 ± 0.6

6.9 ± 0.5

Figure 7. The effect of inflammation and prevention
with GlcN or GVG on serum nitrite concentration in
inflamed rats (n = 6/group); error bars represent standard
deviation. The same character indicates no significant
difference between means at p < 0.05.

Figure 5. Average increase in paw thickness at the
end of the experiment. Error bars represent standard
deviation. The same character indicates no significant
difference between means at p < 0.05; n = 6/group.

DISCUSSION

The effect of the treat ments on the weight gain
(Figure 6) and serum nitrite levels (Figure 7) were
similar to those observed for adjuvant arthritis.

Assay of GVG and GlcN
We developed a sensitive HPLC assay for
simultaneous measurement of GlcN and its ester
derivative, GVG, based on fluorescence detection.
As neither GlcN nor GVG contain fluorophore
groups, we derivatized them to Fmoc-GlcN and –
Fmoc-GVG. Fmoc-Cl has been used since 1980s
for HPLC analysis of amino acids (7). It rapidly
and almost completely reacts with primary and
secondary amines under alkaline conditions. The
solvent gradient program and the addition of 0.1%
acetic acid to the mobile phase resulted in sharp
and resolved peaks (Figure 1). Most of the plasma
interfering peaks eluted before the appearance of
the peaks of interest. The derivatization method
yields two equal sized but completely resolved
anomers (stereoisomers of cyclic sugars that differ
in their configuration at the anomeric carbon) peaks
(8). The excessive amount of the derivatizing agent
was removed by adding amantadine to form a
hydrophobic complex that eluted at the end of the
run time and before the next injection. To prevent

Figure 6. The average percent weight gain (+SD) from
baseline. Error bars represent standard deviation. The
same character indicates no significant difference
between means at p < 0.05; n = 6/group.
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In general, the activation of the prodrug such as
GVG after its in vivo hydrolysis , is not expected to
raise toxicity concerns since the activation
byproducts are a dipeptide and/or amino acids and
the parent drug (20,24).
The low bioavailability of GlcN is attributed to,
at least, two mechanisms, the inefficiency of the
involved transporters (i.e., GLUT-2) and the loss
due to the uptake by the gut microflora (9). It has
been shown that incubation of 1.25 mg GlcN with
the rat feces results in 95% loss. For GVG only
33% loss was detected over a 2 h incubation period
(Figure 3). The mechanism of this loss is unclear as
it occurs under various conditions (aerobic,
anaerobic and/or 4º C) that may put the mere
involvement of microflora into question.
Nevertheless, the observed fecal stability of GVG
as compared with GlcN may contribute to the
greater bioavailability of the latter.

pump pressure build-up, the injection volume was
set at 5 μL.
The method was linear over the examined
range with suitable sensitivity and acceptable
accuracy and reproducibility.
Bioavailability
All of the three examined di-peptide GlcN esters
demonstrated trends toward a greater oral
bioavailability than the parent compound but the
change reached statistical significance only for
GVG. This is in agreement with the previously
reported seven-fold greater than GlcN permeability
across the everted rat gut for GVG (6). The
enhanced permeability was attributed to the
involvement of PepT1 since incubation in the
presence of PepT1 inhibitor (Gly-Sar) reduced the
process to the level of that observed for GlcN (6).
Our observation may be proven useful in predicting
oral absorption of these compounds following
administration to humans, since rats appear to be
suitable predictors of drug absorption by humans
(16). The high permeability of GVG is due, likely,
to the recognition of the conjugate by the PepT1, as
a specific PepT1 substrate; Gly-Sar completely
inhibited transport of GVG (6). In general, the 3dimensional conformation properties of a substrate
govern whether a substrate has affinity for PepT1
(17-19). GVG seemed to have the appropriate
stereochemical and conformational features. There
are several other examples in which researchers
have attempted to improve oral absorption of
various poorly absorbed drugs via attachment to
amino acids or dipeptides in order to resemble
PepT1 substrates, mostly through ester bonds (2023). Similar to GVG, the glycine-valine ester
prodrug of acyclovir appeared to be more
efficiently absorbed across the intestinal mucosa as
compared to other ester derivatives (20).
GVG has been shown to be relatively stable in
the gut; it readily crosses the gut wall and rapidly
yields the parent drug upon incubation with liver
homogenates (6). Although it has been shown that
GVG remains intact during movement from
mucosal toward serosal side in the rat small
intestine (6), we were not able to detect any intact
GVG in the systemic circulation. In other words
GVG seems to be transported into the portal vein
and then cleaved into GlcN and the di-peptide
moiety either in the liver.

Efficacy
The rat model of AA mimics human rheumatoid
arthritis which has been vastly used for decades to
assess the efficacy of antirheumatic agents (10).
We used this model to compare the antiinflammatory effects of GVG with GlcN.
Assuming a three-fold greater bioavailability of
GVG as compared with GlcN, we first compared
30 mg/kg/day of the former with 90 mg/kg/day
(GlcN equivalent) of the latter to assess the efficacy
of the same GlcN exposure following
administration of the two different compounds. We
noticed that the treatments were equally effective in
preventing adjuvant arthritis (Figure 5), reduced
body weight gain (Figure 6) and increased serum
nitrite level (Figure 7). Considering the fact that the
oral administration of GVG yields only GlcN in the
systemic circulation, one can suggest that the
greater potency of GVG is due to the corresponding
higher GlcN bioavailability after administration of
the prodrug as compared to the parent compound.
To further confirm the observation, we compared
the two compounds following daily treatment with
20 mg/kg/day (GlcN equivalent), which was known
to be below the GlcN effective dose range (13).
The GVG and not GlcN regimen was effective in
completely preventing the experimental arthritis.
This further confirms that, at the dosage level that
GlcN is not fully effective, GVG prevents the
emergence of adjuvant arthritis.
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4.

Effect of inflammation of GVG
pharmacokinetics
Inflammation may alter clearance of drugs that are
efficiently metabolized drugs (25) and also
influence the expression of some transporters (11).
Inflammation did not result in such an effect on
GVG since the plasma GlcN concentration-time
curves following GVG administration under
healthy and inflammatory conditions were almost
superimposable (Figure 4). This suggest a lack of
effect of inflammation on the activation of the
prodrug and/or clearance of the active compound
(glucosamine) as has been reported earlier (1).
Similarly, according to Radeva et al (2007),
experimentally-induced
rat
colitis,
another
inflammatory condition, does not alter the
bioavailability of cephalexin or valacyclovir, two
known PepT1 substrates despite certain
modifications in the transporter mRNA expression
(12).

5.
6.

7.

8.

9.

CONCLUSION
10.

A novel dipeptide ester of GlcN, GVG, is found to
have an increased bioavailability assessed using a
novel HPLC method. GVG exhibited increased
anti-inflammatory property through a greater GlcN
delivery into the systemic circulation. The
pharmacokinetics of GlcN delivered through GVG
is not influenced by adjuvant arthritis. If the present
nonclinical data are extrapolated to humans, GVG
can be considered as an alternative to other
antiinflammatory agent that have gastrointestinal
(26), renal (27) and/or cardiovascular (28) side
effects.

11.

12.

13.
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